Summit Therapeutics (SMMT) Expected to Announce Quarterly Earnings on Thursday

Summit Therapeutics (NASDAQ:SMMT) is expected to post its Q2 2026 results after the market closes on Thursday, July 23rd. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $0.1090 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 23, 2026 at 4:30 PM ET.

Summit Therapeutics (NASDAQ:SMMT) last posted its earnings results on Friday, May 1st. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, analysts expect Summit Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Summit Therapeutics Stock Performance

Summit Therapeutics stock opened at $13.81 on Friday. The stock has a market cap of $10.72 billion, a P/E ratio of -8.63 and a beta of -1.26. The firm’s fifty day moving average price is $15.43 and its 200-day moving average price is $16.79. Summit Therapeutics has a fifty-two week low of $12.55 and a fifty-two week high of $30.98.

Insider Buying and Selling

In other news, CEO Robert W. Duggan acquired 3,810,000 shares of Summit Therapeutics stock in a transaction that occurred on Friday, June 12th. The stock was bought at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the completion of the transaction, the chief executive officer owned 573,883,879 shares in the company, valued at $7,529,356,492.48. The trade was a 0.67% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mahkam Zanganeh purchased 3,810,000 shares of Summit Therapeutics stock in a transaction dated Friday, June 12th. The shares were acquired at an average cost of $13.12 per share, with a total value of $49,987,200.00. Following the transaction, the chief executive officer directly owned 573,883,879 shares in the company, valued at approximately $7,529,356,492.48. The trade was a 0.67% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 7,870,000 shares of company stock valued at $103,616,900 over the last 90 days. Company insiders own 83.50% of the company’s stock.

Institutional Investors Weigh In On Summit Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SMMT. Price T Rowe Associates Inc. MD raised its position in shares of Summit Therapeutics by 106.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,371,415 shares of the company’s stock valued at $163,907,000 after purchasing an additional 4,832,592 shares during the period. State Street Corp grew its stake in shares of Summit Therapeutics by 4.3% in the 4th quarter. State Street Corp now owns 6,636,361 shares of the company’s stock worth $116,070,000 after buying an additional 274,425 shares in the last quarter. Geode Capital Management LLC increased its stake in Summit Therapeutics by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,147,480 shares of the company’s stock worth $55,063,000 after acquiring an additional 14,745 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Summit Therapeutics by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 892,629 shares of the company’s stock valued at $15,612,000 after purchasing an additional 16,239 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Summit Therapeutics by 16.1% during the third quarter. Bank of America Corp DE now owns 657,313 shares of the company’s stock valued at $13,580,000 after acquiring an additional 91,166 shares during the last quarter. Institutional investors own 4.61% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on SMMT shares. Piper Sandler decreased their price objective on shares of Summit Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Friday, May 1st. Stifel Nicolaus assumed coverage on Summit Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $45.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Summit Therapeutics in a research note on Tuesday, April 21st. HC Wainwright restated a “neutral” rating on shares of Summit Therapeutics in a report on Wednesday. Finally, Truist Financial upgraded shares of Summit Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $26.97.

About Summit Therapeutics

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.